+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Utility of Echocardiography as Screening for Late-onset Anthracycline-induced Cardiotoxicity in Pediatric Cancer Survivors: Observations from the First Decade After End of Therapy



Utility of Echocardiography as Screening for Late-onset Anthracycline-induced Cardiotoxicity in Pediatric Cancer Survivors: Observations from the First Decade After End of Therapy



Journal of Pediatric Hematology/Oncology 40(5): E283-E288



Current screening guidelines are available for anthracycline-induced cardiotoxicity. However, the utility of echocardiogram screening for late-onset anthracycline cardiotoxicity especially in the decade immediately after end of therapy is debatable. A retrospective chart review of patients seen in the Thriving after Cancer Clinic at Rady Children's Hospital January 2006 to December 2013 was performed. Treatment data, echocardiogram results, cardiology referral notes and cardiac medication data were abstracted from anthracycline-exposed survivors. Descriptive and univariate comparative statistics were performed. Of 368 patients (45% female, median 5.3 y old at diagnosis [range 0 to 18.3], median 5.0 y from end of therapy [EOT] [range 0 to 18.2]), a total of 4 patients (10-year cumulative incidence after EOT 1.3%; 95% confidence interval, 0.1%-19.7%) required cardiac medication for late-onset cardiotoxicity (>1 y after EOT). Those requiring medication for late-onset cardiotoxicity were exposed to more anthracyclines than survivors without cardiotoxicity (median, 360 mg/m [range, 300 to 375 mg/m] vs. 182 mg/m [range, 26 to 515 mg/m], P=0.009). None had neck or chest radiation. In this population, medication initiation for late-onset anthracycline cardiotoxicity was limited predominantly to the first 3 years after EOT, with the next >13 years after EOT. These findings add to the growing body of literature assessing current guidelines to inform improvements in screening practices of survivorship providers.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065660722

Download citation: RISBibTeXText

PMID: 29432303

DOI: 10.1097/MPH.0000000000001087


Related references

The use of metabolic stress testing and exercise stress echocardiography in pediatric cancer survivors to detect early stages of late-onset anthracycline induced cardiotoxicity. Journal of Investigative Medicine 48(5): 235A, 2000

Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatric Research 39(3): 504-512, 1996

Late echocardiography assessment of systolic and diastolic function of the left ventricle in pediatric cancer survivors after anthracycline therapy. Journal of Pediatric Hematology/Oncology 29(11): 761-765, 2007

Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography. Echocardiography 35(2): 234-240, 2017

Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?. Pediatric Hematology and Oncology 31(3): 237-252, 2015

Late-onset anthracycline-induced cardiotoxicity. Medicina Clinica 133(8): 311-313, 2009

Clinical prediction models for anthracycline-associated cardiotoxicity among pediatric cancer survivors--ready for prime time?. Pediatric Blood and Cancer 60(8): 1245-1246, 2013

Utility of echocardiographic screening for late-onset cardiomyopathy in breast cancer survivors treated with cardiotoxic chemotherapy.. 2007

Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. Hematology 17(3): 151-156, 2013

Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circulation. Cardiovascular Imaging 6(6): 873-880, 2014

Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatric Blood and Cancer 62(1): 123-127, 2015

Tissue Doppler Imaging and Focal, Late-Onset Anthracycline-Induced Cardiovascular Disease in Long Term Survivors of Childhood Cancer: A Research Article. Journal of Clinical and Diagnostic Research 10(8): Sc01-Sc04, 2016

Late cardiotoxicity following anthracycline therapy for childhood cancer. Progress in Pediatric Cardiology 8(3): 121-138, 1998

Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance. Circulation. Cardiovascular Imaging 12(5): E008777, 2019

Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography. Turkish Journal of Pediatrics 40(3): 373-383, 1998